Genome editing is a technology that enables scientists to make specific changes to the DNA of living organisms. It involves using a variety of techniques, such as CRISPR/Cas9, to precisely target and alter the DNA sequence of a living organism, allowing for the introduction of new genes or the removal of existing ones. Genome editing has a wide range of applications in areas such as agriculture, medicine and biotechnology, offering the potential to improve human health and increase crop yields.

EdiGene  is dedicated to the development of genome editing technology for human health. Genome editing technology enables the targeted modification of genetic information in human cells, including gene knockout, knock-in and targeted mutations. They aim at providing the high quality products and services for the patients, the pharmaceutical industry, and the scientific research community with the most advanced genome editing technology.EdiGene innovates and applies genome editing technology to developing human therapeutic products. Their therapeutic approach is to treat diseases at the molecular level, making gene therapy safer and more effective.

PLANTeDIT is the first biotech company dedicated to use patented next generation genome editing tools CRISPR/Cas9 RNPs®. Our mission is to produce non-transgenic, regulatory free, sustainable, consumer oriented genome edited plant products .

Bioengineering Lab develops products that can contribute to society using genome editing technology. 

Biotechnology's strength is to examine and use genes (DNA). A gene is a blueprint based on various characteristics of living things. The latest equipment called next-generation sequencer is mainly used to investigate. 
The technology called genome editing is used. In other words, the company believes that the mission of the Bioengineering Lab is to clarify the information on the blueprints of organisms called genes and to develop products that can contribute to society using genome editing technology.

TargetGene was founded in 2012 by drs. Dan Weinthal and Yoel Shiboleth. They invented RNA-guided nucleases for genome editing in 2011. Their patent has recently been granted in the US following grants in many other jurisdictions .

InVivo Biosystems provides essential services to help pharmaceuticalnutraceuticalbiotechnology companies accelerate their research and drug development efforts. An expert in genome editing, we create custom genome edited C. elegans and zebrafish models to enable aging and other disease studies. We're passionate about creating an inclusive workplace that encourages supports and celebrates diversity .

Caribou is a clinical-stage biopharmaceutical company founded by pioneers in CRISPR genome editing. It is developing a pipeline of genome-edited off-the-shelf immune cell therapies for the treatment of cancer. Our mission is to develop innovativetherapeutics for patients with devastating diseases through novel genome editing.

ToolGen, a biotechnology company, focuses on the development of genome editing technology. Its products include gRNA/Cas9 purified that provides ready-to-use reagents for genome engineering experiments; gRNA/Cas9 plasmid that offers tools for genome editing experiment; and recombinant Cas9 protein that offers ready-to-use reagents for genome engineering experiments. 

ToolGen also offers genome-edited cell line; genome-edited mouse/rat; and genome-edited plant services, as well as surrogate reporter synthesis and in-del analysis services. Its products are used in research applications. 

ToolGen began operation in 1999, with its headquarters in Seoul in South Korea. ToolGen is a subsidiary of NSN.

ARCUS is a precise and versatile genome editing technology discovered and developed by scientists at precision biosciences. It uses sequence-specific DNA-cutting enzymes, or nucleases, to insert (knock in), remove, or repair DNA of living cells and tissues. The technology is being used to develop a new class of medicines designed to overcome and potentially cure, hard-to-treat conditions .

Director shoko murase has been incumbent since February 2017. Director ryo okumura has more than 20 years of drug discovery research at daiichi. Kiyokazu iwata is the co-founder and managing director of the company .

TargetGene was founded in 2012 by drs. Dan Weinthal and Yoel Shiboleth. Our patent has recently been granted in the US following grants in many other jurisdictions. We have licensed some applications of the platform, and are now partnering with a therapeutics company.

Search and
explore companies

Genome Editing

For more optimized search results,
use multiple english keywords and apply filters

Search and explore companies

Company size

Location